Neutrophil-to-Lymphocyte Ratio After Definitive Concurrent Chemoradiotherapy Predicts Survival in Patients With Esophageal Squamous Cell Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Hyeon Kang | - |
dc.contributor.author | Park, Younghee | - |
dc.contributor.author | Koo, Taeryool | - |
dc.contributor.author | Park, Hae Jin | - |
dc.contributor.author | Lee, Me Yeon | - |
dc.contributor.author | Chang, Ah Ram | - |
dc.contributor.author | Hong, Semie | - |
dc.contributor.author | Bae, Hoonsik | - |
dc.date.accessioned | 2021-09-10T05:50:39Z | - |
dc.date.available | 2021-09-10T05:50:39Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 0258-851X | - |
dc.identifier.issn | 1791-7549 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18956 | - |
dc.description.abstract | Background/Aim: Lymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio represent systemic immune-inflammatory responses. We evaluated the association between immune-inflammatory cell ratios and prognosis in esophageal squamous cell carcinoma (ESCC) patients who underwent definitive concurrent chemoradiotherapy (dCCRT). Patients and Methods: Medical records of 68 ESCC patients in three institutions who underwent dCCRT between 2006 and 2017 were reviewed. The immune-inflammatory cell ratios were calculated before and after dCCRT. Results: The median follow-up time was 11.4 months. The 3-year overall survival (OS) rate was 21.6%. Among the immune-inflammatory cell ratios, lower post-dCCRT neutrophil-to-lymphocyte ratio (NLRpost) was associated with better OS (median 15.2 vs. 9.7 months, p=0.030). Patients with lower NLRpost had more improved OS when adjuvant chemotherapy was administered following dCCRT (median 16.6 vs. 4.8 months,& nbsp;p<0.001). Conclusion: NLRpost may be useful in predicting OS in ESCC patients after dCCRT. Furthermore, NLRpost might play a role in establishing adjuvant therapy plans following dCCRT. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | International Institute of Anticancer Research | - |
dc.title | Neutrophil-to-Lymphocyte Ratio After Definitive Concurrent Chemoradiotherapy Predicts Survival in Patients With Esophageal Squamous Cell Carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 그리이스 | - |
dc.identifier.doi | 10.21873/invivo.12359 | - |
dc.identifier.scopusid | 2-s2.0-85101900630 | - |
dc.identifier.wosid | 000648906100025 | - |
dc.identifier.bibliographicCitation | In Vivo, v.35, no.2, pp 1133 - 1139 | - |
dc.citation.title | In Vivo | - |
dc.citation.volume | 35 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 1133 | - |
dc.citation.endPage | 1139 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | TUMOR MICROENVIRONMENT | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTOR | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Chemoradiotherapy | - |
dc.subject.keywordAuthor | esophageal squamous cell carcinoma | - |
dc.subject.keywordAuthor | neutrophil-to-lymphocyte ratio | - |
dc.subject.keywordAuthor | inflammation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.